Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Antileishmanial activity of Hi-antihistamine drugs and cellular alterations in Leishmania (L.) infantum

Texto completo
Autor(es):
Mendes, Viviane de Melo [1] ; Tempone, Andre Gustavo [1] ; Treiger Borborema, Samanta Etel [1]
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] Adolfo Lutz Inst, Ctr Parasitol & Mycol, Sao Paulo - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: Acta Tropica; v. 195, p. 6-14, JUL 2019.
Citações Web of Science: 0
Resumo

Leishmaniases are infectious diseases caused by protozoan parasites Leishmania and transmitted by sand flies. Drug repurposing is a therapeutic approach that has shown satisfactory results in their treatment. Analyses of antihistaminic drugs have revealed their in vitro and in vivo activity against trypanosomatids. In this way, this study evaluated the antileishmanial activity of H1-antihistamines and identified the cellular alterations in Leishmania (L.) infantum. Cinnarizine, cyproheptadine, and meclizine showed activity against promastigotes with 50% inhibitory concentration (IC50) values between 10-29 mu M. These drugs also demonstrated activity and selectivity against intracellular amastigotes, with IC50 values between 20-35 mu M. Fexofenadine and cetirizine lacked antileishmanial activity against both forms. Mammalian cytotoxicity studies revealed 50% cytotoxic concentration values between 52 - > 200 mu M. These drugs depolarized the mitochondria membrane of parasites and caused morphological alterations, including mitochondrial damage, disorganization of the intracellular content, and nuclear membrane detachment. In conclusion, the L. infantum death may be ascribed by the subcellular alterations followed by a pronounced decrease in the mitochondrial membrane potential, indicating dysfunction in the respiratory chain upon Hl-antihistamine treatment. These H1-antihistamines could be used to explore new routes of cellular death in the parasite and the determination of the targets at a molecular level, would contribute to understanding the potential of these drugs as antileishmanial. (AU)

Processo FAPESP: 18/10279-6 - Seleção e otimização de novos candidatos a fármacos para Leishmaniose e Doença de Chagas
Beneficiário:André Gustavo Tempone Cardoso
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 14/24908-4 - Avaliação da atividade antileishmania de fármacos anti-histamínicos e identificação de alterações celulares relacionadas à resposta terapêutica em Leishmania (Leishmania) infantum
Beneficiário:Viviane de Melo Mendes
Linha de fomento: Bolsas no Brasil - Iniciação Científica